



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

University of Auckland Library
LIBRARY
SCHOOL OF MEDICINE
PARK ROAD, AUCKLAND

THE EFFECTIVENESS OF MEDICINES

The Relationship between Patient and Prescriber Expectations of Effectiveness of Medicines and Compliance

Gail Jocelyn Ware

A thesis submitted for the Degree of Doctor of Philosophy,
Faculty of Medicine and Health Sciences, University of Auckland, 1997.

ABSTRACT

Effectiveness of medicines as reported in the literature can be difficult to interpret and explain to patients in clinical practice. A patient-orientated measure of effectiveness, the Category of Effectiveness (COE) was developed in 1988 by Dr Holford, Department of Pharmacology and Clinical Pharmacology, University of Auckland, School of Medicine. This was designed to examine the effectiveness of medicines in terms of easily understood patient-orientated outcomes which may influence the patient's daily living or quality of life.

As part of their pharmacology training, third-year medical students were assigned two medicines to evaluate in terms of COE and asked to calculate a rate/1000 treatments or rate/1000 treatment years i.e. a Rate of Effectiveness (ROE). Interviews with three health professionals to obtain their opinions of the assigned medicines in terms of COE and ROE were recorded. An ordered scale of effectiveness, the Likelihood of Effectiveness (LOE), was developed by Dr Holford and the author in order to review these student projects. A review by the author of 201 of these projects over a five year period, suggests that health professionals expectations of some commonly prescribed medicines are over-optimistic.

A literature search to obtain effectiveness information in terms of COE and LOE of twelve commonly prescribed medicines, Augmentin, cefaclor, beclomethasone, salbutamol, atenolol, captopril, enalapril, ranitidine, paracetamol, diclofenac, aspirin, and triazolam was undertaken. Such information was found to be limited in the literature as clinical trial results are seldom expressed in such terms.

Opinions of patients and prescribers about The Category of Effectiveness (COE) and Likelihood of Effectiveness (LOE) of commonly prescribed medicines have not been examined in clinical practice. The influence these may have on medicine use was therefore surveyed for the twelve medicines listed above. One hundred and fifty-three patients received 247 prescriptions for one or more of these medicines. Expectations of patient and corresponding prescriber were similar in terms of COE, but LOEs differed significantly for 8 of the 12 medicines. Neither COE nor LOE were significantly related to patient compliance which was measured after 5-10 days. Most compliance-failure was seen in patients whose medicine was newly prescribed for short-term treatment. Information other than basic instructions was received by <25% of patients from either the prescriber or the pharmacist. At the surgery/hospital only 19% of patients remembered receiving written

information about their medicine, which increased to 22% at the home visit. Of the patients who completed the medicines information questionnaire, only 59/152 (38.6%) would like more general information about their medicines. Despite this, 139/152 (91.4%) patients would like more specific information on how their medicine works, and 130/152 (85.5%) want to know how well it can be expected to work. This information has not been given to patients in the past.

It was hypothesised that providing effectiveness information to patients may have some effect on compliance. The influence on compliance that providing written medicine effectiveness information as pamphlets from community pharmacists may have, was examined for 211 patients in a double-blind controlled trial. Patients who presented a prescription for beclomethasone for asthma or enalapril for hypertension were invited to participate. Each patient received one of three pamphlets, 1. specific medicine information pamphlet, 2. specific medicine information plus effectiveness information, 3. a control pamphlet containing general medicine information. Medicine knowledge was significantly increased by both the medicine information pamphlet ($p=0.028$) and the medicine and effectiveness information pamphlet ($p=0.016$) compared to control. Significantly more beclomethasone than enalapril patients showed compliance-failure ($p=0.001$) although this was independent of the pamphlet given. Expectations of LOE were related to patient compliance for beclomethasone patients, but not for enalapril patients. Significantly more beclomethasone patients with higher expectations of LOE were compliant ($p=0.017$). Satisfaction with the information contained in the pamphlet had a positive effect on patient compliance with beclomethasone individually. Patient-orientated measures of effectiveness such as COE (Category of effectiveness) and LOE (Likelihood of effectiveness) can identify patient expectations, increase patient knowledge and may provide some insight into patient compliance failure.

PRESENTATIONS AND PUBLICATIONS ARISING FROM THIS THESIS

Paper presented at ASCEPT Conference, Brisbane 1993

Ware GJ, Holford NHG. Effectiveness of medicines - the influence of patient and prescriber expectations of effectiveness

Published in Proceedings of ASCEPT 1993

Paper presented at the ASCEPT (New Zealand) Conference Wellington 1995

Ware GJ, Holford NHG. Knowledge of the effectiveness of medicines - does it alter patient compliance?

Poster presented at the ASCEPT Conference, Adelaide 1995

Ware GJ, Holford, NHG. Knowledge of the Effectiveness of Medicines - Does it alter compliance with long-term medicines?

Abstract Published in Proceedings ASCEPT 1995 p158

Paper presented at the APSA Conference Adelaide 1995

Abstract Published

Ware GJ., Holford, NHG. Patients' perceptions of the effectiveness of their medicines - Does this alter long-term compliance? (Abstract) Aust J Hosp Pharm 1996;26:4:506

Paper presented at the PSA Congress Melbourne 1996

Abstract Published

Ware GJ., Holford, NHG. Pharmacists and medicine information - a key aspect of Pharmaceutical Care (Abstract). Australian Pharmacist 1996;15:11(Suppl):5-6.

ACKNOWLEDGEMENTS

This thesis was made possible by the advice and encouragement of my supervisors Dr. Nick Holford and Dr. Robin Briant. They have given freely of their time and advice which has been greatly appreciated. I would particularly like to thank Dr. Holford for his continued support and speedy replies via e-mail, which has enabled me to be with my husband in Melbourne whilst writing up this research. My thanks also to Dr. Bruce Arroll who has provided valuable advice for the general practice project and given his time reviewing CHAPTER 4. The Department of General Practice has also provided comments and advice for the general practice project.

Particular thanks also to Gregory Gamble, Biostatistician, from the Clinical Trials Unit who has given assistance both personally and via e-mail in working with SAS.

This work would not have been possible without the help and assistance of the general practitioners who allowed me to conduct the survey in their practices and the staff at the medical wards at Auckland hospital and I am most grateful to them. My colleagues in community pharmacy have also provided unceasing support and particular thanks to those who participated in the pamphlet project.

I would like also to acknowledge the financial assistance of the Pharmacy Education and Research Foundation for the pamphlet project and also Glaxo N.Z. Pty Ltd. who funded the electronic scales used in this project.

The staff and members of the Department of Pharmacology and Clinical Pharmacology have provided continued help and encouragement for this work. In addition I would also like to acknowledge the help of the Department of Pharmacology, and the Department of Pharmacy Practice at Monash University, Melbourne who have assisted with e-mail and library access respectively during the writing of this thesis.

I would also like to thank my family on both sides of the Tasman who have helped me over the past four years, particularly my husband Neil without whose unfailing patience and support this thesis could not have been completed. After a business transfer to Melbourne, he was happy for me to complete this research in Auckland, before joining him there. This thesis would not have been possible without such encouragement.

TABLE OF CONTENTS

ABSTRACT	ii
PRESENTATIONS AND PUBLICATIONS	iv
ACKNOWLEDGEMENTS	v
TABLE OF CONTENTS	vi
LIST OF TABLES	xiv
LIST OF FIGURES	xvii
LIST OF APPENDICES	xviii
LIST OF ABBREVIATIONS	xix

SECTION 1 - INTRODUCTION

CHAPTER 1 - MEDICINES - Effectiveness, Information and Patient Compliance 20

PART A - MEDICINE EFFECTIVENESS

1.1 Medicine and Health.	21
1.1.1 The effectiveness of medicines	22
1.1.1.1 Efficacy	23
1.1.1.2 Effectiveness	23
1.1.1.3 Appropriate use by the prescriber	24
1.1.1.4 Compliance	25
1.1.2 Measures of effectiveness	25
1.1.3 Are these measures adequate?	25
1.1.4 What is important to the patient?	26
1.1.5 How can we express medicine effectiveness in more meaningful terms?	26

PART B - MEDICINE INFORMATION

1.2 Introduction	29
1.2.1 For the Prescriber	29
1.2.1.1 Sources of information	29
1.2.1.2 Information available for new medicines.	32
1.2.1.3 Dissemination of the results of clinical trials.	32
1.2.1.4 Limitations	33
1.2.1.5 Academic detailing	35

1.2.2 For the Patient	36
1.2.2.1 Patient medicine information requirements.	36
1.2.2.2 Production of Pamphlets	38
1.2.2.3 Method of distribution of medicine information	38
1.2.2.4 Current requirements for written patient information.	39
PART C - PATIENT COMPLIANCE	
1.3 Introduction	40
/ 1.3.1 Definition and Terminology	41
/ 1.3.2 Incidence and Patterns of Compliance-failure	41
/ 1.3.3 Measures of Compliance	42
1.3.4 Understanding Compliance Behaviour	44
1.3.5.1 Related to the prescriber	45
1.3.5.2 Related to the patient	46
1.3.6 The Consequences of Compliance-failure	48
1.3.6.1 In clinical trials	48
1.3.6.2 For the patient	49
/ 1.3.7 Strategies to Improve Compliance	50
1.3.7.1 For the prescriber	50
1.3.7.2 For the patient	51
/ 1.3.8 Discussion	53
/ 1.3.9 Conclusion	55
PART D - THESIS PROPOSAL	
1.4 THESIS PROPOSAL	56
CHAPTER 2 - HEALTH PROFESSIONALS OPINIONS OF EFFECTIVENESS OF	
MEDICINES - A Review of Student Projects	57
2.1 Introduction	57
2.2 Methods	59
2.3 Results	60
2.3.1 Antibiotics	61
2.3.2 Antiasthmatic medicines	62
2.3.3 Antihypertensives	64
2.3.4 Gastrointestinal medicines	66
2.3.5 Pain relief - paracetamol	68
2.3.6 NSAIDS	68

2.3.7 Aspirin and thrombolytics	69
2.3.8 Hypnotic	70
2.4 Discussion	71
2.4.1 Antibiotics	73
2.4.2 Antiasthmatics	74
2.4.3 Antihypertensives	75
2.4.4 Gastrointestinal medicines	76
2.4.5 Paracetamol	77
2.4.6 NSAIDS	77
2.4.7 Aspirin and thrombolytics	78
2.4.8 Hypnotics	79
2.5 Summary	79
2.6 Conclusion	80

SECTION 2 - STANDARDS OF EFFECTIVENESS

CHAPTER 3 - EFFECTIVENESS OF TWELVE COMMONLY PRESCRIBED

MEDICINES	81
3.1 Introduction	81
3.2 Methods	82
3.2.1 Measures of effectiveness	82
3.2.1.1 Category of effectiveness (COE)	82
3.2.1.2 Likelihood of effectiveness (LOE)	83
3.2.2 Medicines evaluated	84
3.2.3 Literature Review	85
3.3 Results	85
3.3.1 Augmentin	85
3.3.1.1 Upper respiratory tract infections	86
3.3.1.2 Lower respiratory tract infections	86
3.3.1.3 Acute otitis media	87
3.3.1.4 Urinary tract infections	88
3.3.2 Cefaclor	90
3.3.2.1 Otitis media	90
3.3.2.2 Lower respiratory tract infections - bronchitis and pneumonia	90

3.3.3 Beclomethasone	92
3.3.3.1 Asthma	92
3.3.3.2 Allergic rhinitis (Hay Fever)	95
3.3.4 Salbutamol	96
3.3.4.1 Asthma	98
3.3.5 Atenolol	99
3.3.5.1 Post Myocardial infarction	99
3.3.5.2 Angina	100
3.3.6 Captopril	102
3.3.6.1 Congestive Heart Failure	103
3.3.6.2 Hypertension	105
3.3.7 Enalapril	106
3.3.7.1 Congestive heart failure (CHF)	106
3.3.7.2 Hypertension	107
3.3.8 Ranitidine	109
3.3.8.1 Ulcer treatment	109
3.3.8.2 Prevention of Ulcer Recurrence	111
3.3.9 Paracetamol	111
3.3.9.1 COE6 (fewer painful days) - LOE	112
3.3.10 Diclofenac	115
3.3.10.1 Rheumatoid arthritis	115
3.3.10.3 Pain relief	117
3.3.10.4 Trauma	118
3.3.11 Aspirin	119
3.3.11.1 Antiplatelet activity	120
3.3.12 Triazolam	125
3.4 Discussion	128
3.5 Conclusion	129

SECTION 3 - RESEARCH PROJECTS

CHAPTER 4 - THE INFLUENCE ON MEDICINE USE OF PRESCRIBER AND PATIENT EXPECTATIONS OF MEDICINES	130
4.1 Introduction	130
4.2 Expectations of Medicine Effectiveness	131

4.2.1 The patient	131
4.2.2 The prescriber	131
4.2.3 Compliance with prescribed medicine treatment	132
4.2.4 Patient medicine information	132
4.3 Aims	133
4.4 Methods	134
4.4.1 Commonly prescribed medicines	134
4.4.2 Measures of medicine effectiveness	134
4.4.3 Project setting	134
4.4.3.1 General practice setting	134
4.4.3.2 Hospital Setting	135
4.4.4 Recruitment of patients	135
4.4.4.1 Patients from general practice	135
4.4.4.2 Recruitment of hospital patients	137
4.4.5 Measures	137
4.4.5.1 Potential predictor variables	137
4.4.5.2 Patient Decisions to Take The Prescribed Medicines	138
4.4.5.3 Patient Medicine Information Needs	138
4.4.5.4 Patient numbers	139
4.4.6 Analysis.	139
4.4.6.1 Methods	139
4.4.6.2 Possible Sources of Bias	140
4.4.7 Pilot study evaluation	141
4.5 Results - Part A and B Medicine Effectiveness and Compliance.	141
4.5.1 General practitioners	141
4.5.2 Patient population	142
4.5.2.1 Ethnicity	142
4.5.2.2 Age and gender distribution	142
4.5.2.3 Home visits	144
4.5.3 Medicines	144
4.5.3.1 Severity of illness.	146
4.5.4 Opinions on measures of effectiveness	147
4.5.4.1 Category of effectiveness	147
4.5.4.2 Likelihood of effectiveness (LOE)	149
4.5.5 Medicine information knowledge	149

4.5.6 Compliance	151
4.6 Results - Part C. Medicine Information Questionnaire	158
4.6.1 Patient perceptions of medicine information needs	158
4.6.1.1 Question A: Current sources of medicine information ..	158
4.6.1.2 Question B: More information	160
4.6.1.3 Question C: Who to talk to about medicines	160
4.6.1.4 Question D: Preference for form of medicine information or extra information	162
4.6.1.5 Question E: Effectiveness information	162
4.6.1.6 Question F: Provision of medicine information service ..	164
4.6.1.7 Question G: The importance of such a service to patients	165
4.6.1.8 Question H: Frequency of collecting the medicine prescribed	165
4.6.1.9 Question K: Cost of the prescription to the patient	165
4.6.1.10 Question L: Perceived frequency of taking medicines as directed	166
4.7 Discussion	167
4.7.1 Category of effectiveness (COE)	167
4.7.2 Likelihood of effectiveness	168
4.7.3 Compliance	172
4.7.4 Medicine information perceptions	173
4.7.5 Limitations	177
4.8 Conclusions	177
4.8.1 Part A and B: Medicine effectiveness and compliance	177
4.8.2 Part C	178
4.9 Implications of this Project	178
 CHAPTER 5 - DOES INFORMATION ON EFFECTIVENESS ALTER COMPLIANCE WITH LONG-TERM MEDICINES?	180
5.1 Introduction	180
5.2 Aims	180
5.3 Methods	180
5.3.1 Project type	180
5.3.2 Pamphlets	181

5.3.2.1 Development of pamphlets	181
5.3.2.2 Testing of pamphlets	181
5.3.2.3 Specific Medicine Information	182
5.3.2.4 Medicine and Effectiveness information (COE and LOE)	182
5.3.2.5 General Medicine Information	183
5.3.3 Compliance	183
5.3.3.1 Compliance Measures	183
5.3.3.2 Measurement of doses taken	184
5.3.4 Expectations of effectiveness	184
5.3.5 Medicine knowledge	184
5.3.6 Demographics	185
5.3.6.1 Location of Project	185
5.3.6.2 Invitation of Pharmacies	185
5.3.6.3 Recruitment of patients	185
5.3.6.4 Protocol for pharmacists	186
5.3.6.5 Socioeconomic status	187
5.3.6.6 Follow-up home visits	187
5.3.7 Ethics approval and patient confidentiality	188
5.3.8 Analysis	188
5.4 Results	188
5.4.1 Patient population	188
5.4.1.1 Patient Enrolment	188
5.4.1.2 Reasons for withdrawal	190
5.4.1.3 Geographic distribution and ethnicity	191
5.4.1.4 Socioeconomic status	191
5.4.2 Comparability of medicine use by patients	191
5.4.2.1 Gender	191
5.4.2.2 Age	191
5.4.2.3 Total number of medicines taken	192
5.4.2.4 Length of time taking medicines (years)	192
5.4.2.5 Home visits	192
5.4.3 Pamphlets	194
5.4.3.1 Allocation of pamphlets	194
5.4.3.2 Distribution of pamphlets between genders	194

5.4.3.3 Distribution of pamphlets among age-groups	195
5.4.3.4 Distribution of pamphlets among socioeconomic groups	195
5.4.4 Patient Compliance	196
5.4.4.1 Compliance examined as a true/false variable.	196
5.4.4.2 Percent Compliance	199
5.4.4.3 Patient expectations of compliance	200
5.4.4.4 Comparison with self-reported measure	201
5.4.5.1 Category of effectiveness(COE)	201
5.4.5.2 Likelihood of effectiveness(LOE)	203
5.4.6 The Medicine Information Pamphlets	206
5.4.6.1 Effect on Medicine knowledge	206
5.4.6.2 Specific information remembered	209
5.4.6.3 Ease of reading	209
5.4.6.4 Satisfaction	209
5.4.6.5 Kept pamphlet for future reference	210
5.4.7 Interaction with the pharmacist	210
5.5 Discussion	212
5.5.1 Patient expectations of effectiveness	214
5.5.2 Compliance	215
5.5.2.1 Beclomethasone	217
5.5.2.2 Enalapril	219
5.5.2.3 Effect of information pamphlets on compliance	220
5.5.3 Patients' medicine knowledge	222
5.5.4 Limitations	223
5.6 Conclusions	224

SECTION 4 - DISCUSSION AND CONCLUSION

CHAPTER 6 - DISCUSSION	226
CHAPTER 7 - CONCLUSION	235
BIBLIOGRAPHY	237
APPENDICES	

LIST OF TABLES

CHAPTER 2

2-1	Medicine Reports Reviewed	60
2-2	Opinions of COE on Antibiotics	61
2-3	Derived LOE and Rates of Effectiveness of Antibiotics	62
2-4	Opinions on COE of Anti-asthmatics	63
2-5	Derived LOE and Rate of Effectiveness of Anti-asthmatics	64
2-6	Opinions on COE of Antihypertensives	65
2-7	Derived LOE and Opinions on Rate of Effectiveness of Antihypertensives . . .	66
2-8	Opinions on COE of Gastrointestinal Medicines	67
2-9	Derived LOE and Opinions on Rate of Effectiveness of Gastrointestinal Medicines	67
2-10	Derived LOE and Opinions on ROE of Paracetamol	68
2-11	Opinions on COE of NSAIDS	69
2-12	Derived LOE and Opinions on Rate of Effectiveness of NSAIDS	69
2-13	Derived LOE and Opinions on ROE of Aspirin & Thrombolytics	70
2-14	Derived LOE and Rate of Effectiveness of Triazolam	70
2-15	Summary of Health Professionals Opinions of LOE	79

CHAPTER 3

3-1	Medicines Evaluated	84
3-2	Category and Likelihood of Effectiveness of Augmentin	89
3-3	Category and Likelihood of Effectiveness of Cefaclor	91
3-4	Category and Likelihood of Effectiveness of Beclomethasone	94
3-5	Category and Likelihood of Effectiveness of Salbutamol	97
3-6	Category and Likelihood of Effectiveness of Atenolol	101
3-7	Category and Likelihood of Effectiveness of Captopril	104
3-8	Category and Likelihood of Effectiveness of Enalapril	108
3-9	Category and Likelihood of Effectiveness of Ranitidine	110
3-10	Category and Likelihood of Effectiveness of Paracetamol	114
3-11	Category and Likelihood of Effectiveness of Diclofenac	116
3-12	Category and Likelihood of Effectiveness of Aspirin as an Antiplatelet	122
3-13	Category and Likelihood of Effectiveness of Triazolam	126

CHAPTER 4

4-1	Patient Information Needs	138
4-2	Location of General Practices	142
4-3	Age and Gender Distribution for Medicines	144
4-4	Frequency of Prescribing of Medicines	146
4-5	Severity of Illness	147
4-6	Frequency of Opinions on the Category of Effectiveness (COE) at Enrolment.	148
4-7	Frequency of Opinions on the Likelihood of Effectiveness (LOE) at Enrolment	150
4-8	Knowledge of Specific Information about the Medicines at the Surgery/Hospital and the Home Visit	151
4-9	Prescriptions Collected	153
4-10	Compliance in Relation to Setting	153
4-11	Relationship of the Number of Medicines Taken to Compliance	154
4-12	Effect of Age-group on Compliance	155
4-13	Relationship of Compliance to Information given at the Surgery/Hospital	155
4-14	Relationship of Compliance to Information Remembered at the Surgery/Hospital	156
4-15	Relationship of Compliance to the Information Remembered at the Home Visit	156
4-16	Relationship of Patient and Prescriber Expectations of LOE to Compliance . .	158
4-17	Patient Sources of Medicine Information	158
4-18	Medicine Information Requirements	160
4-19	Preferred Provider	160
4-21	Ease of Talking to the Health Professional	162
4-21	Frequency of Health Professional Providing Medicine Information	162
4-22	Effectiveness Information	164
4-23	Type of Medicine Information Service Preferred	164
4-24	Importance of Provision of such a Medicine Information Service	165
4-25	Collection of Prescriptions	165
4-26	Cost to the Patient of Each Prescription Item	166
4-27	Expected Compliance	166
4-28	Suggested Aids for Compliance	166
4-29	Comparison of Prescriber COE and Corresponding Patient LOE	171

CHAPTER 5

5-1	Patient Enrolment	190
5-2	Reasons for Withdrawal	190
5-3	Geographic Distribution and Ethnicity of Patients	191
5-4	Number of Medicines Taken by Each Patient	192
5-5	Length of Time Taking Beclomethasone/Enalapril	192
5-6	Number of Days Between Home Visits	194
5-7	Distribution of Pamphlets	194
5-8	Distribution of Pamphlets among Genders	195
5-9	Distribution of Pamphlets amongst Age-groups	195
5-10	The Number of Compliant Patients as Defined	196
5-11	The Relationship of Patient Specific Variables to Compliance	198
5-12	The Frequency of Compliance amongst Pamphlet Types	198
5-13	The Relationship of Pamphlet Associated Variables to Compliance	199
5-14	Comparison of Patient Expectations of Compliance and Measured Compliance	200
5-15	Results of Morisky Scale Question Score	201
5-16	Category of Effectiveness (COE) in relation to each pamphlet	203
5-17	Likelihood of Effectiveness (LOE) in Relation to Each Pamphlet	204
5-18	Effect of Each Pamphlet on Knowledge (Both Medicines)	206
5-19	Effect of Each Pamphlet on Knowledge (Beclomethasone)	207
5-20	Effect of Each Pamphlet on Knowledge (Enalapril)	207
5-21	Knowledge of Specific Information (Both Medicines) at the Pharmacy and Home Visit 1	209
5-22	Kept Pamphlet for Future Reference	210

LIST OF FIGURES

CHAPTER 1

1-1	Patient Expectations of Effectiveness and Their Influence on Compliance [after The Health Belief Model of Godfrey et al. (Becker et al. 1979)	28
-----	--	----

CHAPTER 4

4-1	Location of General Practices	136
4-2	Patient population	143
4-3	Comparison of Patient and Prescriber COE	145
4-4	Comparison of Patient and Prescriber LOE	145
4-5	Relationship of age to compliance	152
4-6	Effect of COE on Compliance	152
4-7	Effect of LOE on Compliance	152
4-8	Patient Medicine Information Requirements	157
4-9	Preferred Format of Patient Medicine Information	157
4-10	Preferred Provider of Patient Medicine Information	159
4-11	Current Frequency of Patients Receiving Medicine Information from Health Professionals	159
4-12	Patients Requiring Effectiveness Information	161
4-13	Patients Preferred Medicine Information Service	163

CHAPTER 5

5-1	Location of Pharmacies	189
5-2	Patient Population	193
5-3	Compliance - Relationship to Pamphlet Type	197
5-4	Compliance - Patient Expectations vs Measured	197
5-5	Patients' Opinions of Category and Likelihood of Effectiveness	202
5-6	Relationship of Age to Percent Doses Taken Correctly	205
5-7	Effect of Pamphlets on Medicine Knowledge	208
5-8	Patient Satisfaction with Each Pamphlet	211

APPENDIX XIX

A-1a	Relationship of Adherence Index to the Percentage of Compliant Patients . .	301a
A-1b	Relationship of Adherence Scale to the Percentage of Compliant Patients . .	301a

LIST OF APPENDICES

APPENDIX I	Student Project - Ethics Committee Assessment	261
APPENDIX II	Medicine & Effectiveness Project. Ethical Approval	262
APPENDIX III	Patient Information Sheet	263
APPENDIX IV	Patient knowledge Assessment Sheet	265
APPENDIX V	Patient questionnaire - Investigator use	266
APPENDIX VI	Patient Medicines information Questionnaire	261
APPENDIX VII	Prescriber Information Sheet	272
APPENDIX VIII	Prescriber Questionnaire	274
APPENDIX IX	Does Information on Effectiveness alter Compliance - Ethics Approval	276
APPENDIX X	Approval Extension	277
APPENDIX XI	Prescription Code	278
APPENDIX XII	Beclomethasone - Assessment of Aerosol Weights	279
APPENDIX XIII	Pamphlets	280
APPENDIX XIV	Reading Tests	286
APPENDIX XV	Information Sheet for Pharmacists	289
APPENDIX XVI	Protocol for Pharmacists	290
APPENDIX XVII	Patient Information Sheet	291
APPENDIX XVIII	Patient Questionnaires	292
APPENDIX XIX	Medication Adherence Assessment (Morisky et al)	301
APPENDIX XX	Pharmacist Assessment of Involvement in the Project	302

LIST OF ABBREVIATIONS

ACEI	ACE-inhibitor
ADR	adverse drug reaction
BIDS	Bath Information and Data Service
BMA	British Medical Association
CHF	congestive heart failure
COE	category of effectiveness
CPI	consumer product information
CMI	consumer medicine information
CCU	Critical Care Unit
FDA	Food and Drug Administration (USA)
GP	general practitioner
HBM	Health Belief Model
HV	home visit
IPA	Independent Practitioner Association
LOE	likelihood of effectiveness
MI	myocardial infarction
MOS	Medical Outcomes Study
NSAID	non-steroidal anti-inflammatory drug
NHP	Nottingham Health Profile
NNT	number needed to be treated to obtain an effect
OBRA	Omnibus Budget Reconciliation Act
PHARMAC	Pharmaceutical Management Agency Ltd
pHx	past history
QoL	quality of life
RCT	randomised controlled trial
SF-36	Short-Form Questionnaire developed from Medical Outcomes Study
SPC	summary of product characteristics
USPDI	United States Pharmacopeia Drug Information Service